What The UK’s “Non-Statutory” AI Regulatory Framework Means For Medtech
The UK government has proposed a “pro-innovation” AI regulation strategy, which will utilize the expertise of existing regulators and avoid new legislation. But what does this mean for the medtech sector, and how does the UK approach differ from the EU’s AI Act?
You may also be interested in...
Manufacturers of innovative medtech products are more likely to achieve market access in the UK by determining where their product offers the most value to the health system before embarking on evidence generation, a senior figure at NICE has said.
The UK government has set aside £21 million ($27m) to fund the uptake of artificial intelligence-based medtech tools that can be used to diagnose and treat patients faster in hospitals.
The proposed EU AI Act has been challenged by industry in recent years, but views expressed during a panel discussion at the MedTech Forum 2023 point towards increasing support among medtech stakeholders for the landmark legislation.